Methylation Haplotype Analysis for Rare Plasma DNA Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting nucleic acids, particularly in heterogeneous samples like whole blood or plasma, suffer from technical noise and sensitivity limitations when measuring single CpG methylation, making it difficult to accurately determine the tissue of origin or health conditions such as tumors or fetal aneuploidy.
Innovation Solution
The method involves performing methylation analysis on a sample to identify methylation haplotype blocks, which are regions of coordinated methylation status across multiple CpG sites, and using metrics like methylation haplotype load (MHL) and unmethylated haplotype load (uMHL) to quantify and distinguish different tissue types, enabling accurate tissue-of-origin mapping and health condition detection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If single CpG methylation measurement is used, then measurement simplicity is maintained, but measurement precision and sensitivity deteriorate due to technical noise
Solution Approach 1:
The patent segments the genome into multiple CpG sites and measures methylation status at each site individually, then integrates these measurements into haplotype patterns. This segmentation approach transforms a single noisy measurement into multiple coordinated measurements, improving overall measurement precision while maintaining analytical feasibility through systematic processing of the segmented data.
2Reliability
If methylation haplotype blocks are used, then detection sensitivity for rare DNA species is improved, but computational complexity increases
Solution Approach 1:
The patent merges multiple individual CpG methylation measurements into integrated haplotype patterns that represent coordinated methylation states across multiple sites. By combining these measurements into unified haplotype signatures, the method enhances detection sensitivity for rare DNA species while reducing the computational burden of analyzing each CpG site independently, as the merged haplotype patterns serve as consolidated analytical units.
3Quantity of substance
If whole genome bisulfite sequencing is performed, then comprehensive methylation coverage is achieved, but cost and data processing requirements increase
Solution Approach 1:
The patent extracts and focuses analysis on specific genomic regions containing CpG sites that are relevant to tissue-of-origin identification and health condition detection, rather than uniformly analyzing the entire genome. This extraction approach maintains comprehensive coverage of functionally important methylation regions while reducing the overall data volume and processing complexity associated with whole genome bisulfite sequencing.
Data Source
AI summary
Some embodiments relate to a method for detecting the presence of one or more nucleic acids indicative of a health condition, tissue of origin, germ layer of origin or organ of origin in a mixture of nucleic acids comprising performing methylation analysis on a sample comprising a plurality of nucleic acids and determining whether the sample includes a plurality of methylation haplotype blocks indicative of the presence one or more nucleic acids indicative of a health condition, tissue of origin, germ layer of origin or organ of origin wherein the methylation haplotype blocks comprise a plurality of methylation sites for which the methylation status is coordinated.